Nipocalimab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS study.

Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS study.

Journal: Expert review of clinical immunology

Published: February 18, 2026

Precision Immunomodulation in Pregnancy - Lessons from Nipocalimab.

Precision Immunomodulation in Pregnancy - Lessons from Nipocalimab.

Journal: NEJM evidence

Published: January 27, 2026

Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn.

Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn.

Journal: NEJM evidence

Published: January 27, 2026

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.

Journal: American journal of therapeutics

Published: January 08, 2026

The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit-Risk, Autonomy, and Maternal-Fetal Interests.

The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit-Risk, Autonomy, and Maternal-Fetal Interests.

Journal: American journal of perinatology

Published: December 30, 2025

Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia.

Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia.

Journal: American journal of perinatology

Published: December 29, 2025

Body weight distribution of US patients with myasthenia gravis.

Body weight distribution of US patients with myasthenia gravis.

Journal: Journal of medical economics

Published: December 21, 2025

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.

Journal: Advances in therapy

Published: December 16, 2025

Management of autoimmune hemolytic anemia.

Management of autoimmune hemolytic anemia.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

What is in the Neuromuscular Junction Literature?

What is in the Neuromuscular Junction Literature?

Journal: Journal of clinical neuromuscular disease

Published: December 03, 2025

Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.

Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.

Journal: American journal of perinatology

Published: November 25, 2025

Nipocalimab reduces Sjögren disease activity in phase II trial.

Nipocalimab reduces Sjögren disease activity in phase II trial.

Journal: Nature reviews. Rheumatology

Published: November 25, 2025

Showing 1-12 of 63

Last Updated: 04/28/2026